DBV Technologies S.A. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. DBV is a clinical-stage biopharmaceutical company developing Viaskin epicutaneous immunotherapy. Unless otherwise stated, financial amounts below are in U.S. dollars; financial statement figures are generally reported in thousands.
Financial performance and position
| Metric | Q2 2022 / June 30, 2022 | Comparable period / prior year-end |
|---|---|---|
| Operating income | $1.5 million | Q2 2021: ($1.5) million |
| Operating expenses | $25.4 million | Q2 2021: $29.6 million |
| Net loss | $23.0 million | Q2 2021: $30.7 million |
| Basic/diluted loss per share | ($0.35) | Q2 2021: ($0.56) |
| Six-month net loss | $39.7 million | Six months 2021: $60.1 million |
| Cash and cash equivalents | $248.0 million | December 31, 2021: $77.3 million |
| Total liabilities | $40.6 million | December 31, 2021: $47.4 million |
- There were no product sales. Operating income primarily reflected French research tax credits and collaboration-related income from Nestlé Health Science; the filing does not report conventional sales margins.
- Six-month operating expenses were $44.7 million, down 28% year over year. Research and development was $30.8 million, sales and marketing $1.5 million, and general and administrative $12.3 million.
- Six-month operating cash use was $11.7 million versus $66.5 million in 2021; investing cash use was $0.2 million. Financing provided $195.2 million, chiefly from 2022 equity financing. The cash flow statement reports a $12.6 million adverse currency effect.
- The company reported no bank debt; short-term financial debt was $0.2 million. Lease liabilities and contingencies are reported separately. Current liabilities were $30.4 million.
Material changes and financing
- In May, DBV raised gross proceeds of $15.3 million through its at-the-market program. In June, it completed a PIPE raising approximately $194 million gross through ordinary shares and pre-funded warrants.
- The PIPE issued 32.9 million ordinary shares and 28.3 million pre-funded warrants, each exercisable for one ordinary share at €0.10. The warrants were classified as equity. The share issuance and potential warrant exercise create substantial dilution risk.
- Average headcount declined to 87 in the first half of 2022 from 111 a year earlier. Management attributed lower expenses partly to workforce reductions, cost controls, and completion of work on earlier clinical studies.
- Operating income for the first half rose to $4.1 million from $1.5 million, mainly reflecting updated recognition of Nestlé collaboration income. Research tax credit income declined to $3.1 million from $3.7 million.
Clinical outlook, risks, and unusual items
- Viaskin Peanut, ages 4–11: DBV was aligning with FDA on the VITESSE pivotal Phase 3 protocol for a modified patch. It had submitted a briefing package for a Type C meeting, but had not yet disclosed final trial design or projected timelines.
- Viaskin Peanut, ages 1–3: The Phase 3 EPITOPE trial met its primary endpoint. After 12 months, 67.0% of treated subjects met responder criteria versus 33.5% on placebo (p<0.001; difference 33.4 percentage points; 95% CI 22.4%–44.5%). DBV said it would further analyze results and explore regulatory pathways.
- European Union: DBV withdrew its Viaskin Peanut marketing application after the EMA raised a major objection concerning the evidence from a single pivotal study. The company intends to resubmit when data from a second pivotal study are available.
- Management said available cash was expected to fund operations for at least 12 months from the filing date, and to extend several months beyond projected completion of VITESSE. The company also stated cash should cover its operating plan for at least the next 12 months. These are forward-looking estimates, not a guarantee.
- Contractual cash requirements totaled $35.1 million, including $30.6 million under CRO agreements and $4.3 million for operating leases. The filing notes that actual payments may differ and excludes cancellable agreements.
- COVID-19-related travel restrictions had affected enrollment and required clinical-trial adaptations. Other key risks include clinical and regulatory uncertainty, financing conditions, foreign-exchange movements, and potential disruption to third-party providers.
- A U.S. securities class action was dismissed with prejudice on July 29, 2022; plaintiffs had 30 days to appeal. The company said it did not expect a material adverse effect.
- An early termination of the Summit, New Jersey office lease produced a reported $1.2 million income effect, offset by a one-time $1.5 million termination fee. Foreign currency translation contributed to comprehensive loss.
Important facts for investors to verify
- VITESSE’s final protocol, initiation timing, enrollment assumptions, cost, and completion schedule following FDA discussions.
- Full EPITOPE results, including safety, subgroup analyses, durability, and the regulatory path for ages 1–3.
- Cash runway assumptions and whether the reported operating cash use is sustainable; the filing’s MD&A cites $12.3 million of operating cash use for the half-year, while the cash flow statement reports $11.7 million.
- Share dilution and resale overhang from the PIPE shares, 28.3 million pre-funded warrants, and registered equity-plan shares.
- Loss-per-share consistency: the financial statements report a six-month 2022 loss per share of $0.66, while the MD&A narrative states $0.51.
- Any appeal of the class-action dismissal and the timing and outcome of the planned EMA resubmission.